Pure Global
NCT03931161

Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)

Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis
Imperial College Healthcare NHS Trust·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Carotid Artery Stenosis
Drug/Device/Intervention
Evolocumab Auto-Injector [Repatha]
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Imperial College Healthcare NHS Trust
Location
London, United Kingdom
Timeline & enrollment
Phase
Phase 4
Start date
Sep 04, 2019
End date
Sep 04, 2023
Enrollment
60 participants
Primary outcome

Change in lipid-rich necrotic core

Summary

This is a phase IV, randomised, placebo-controlled, double-blind, parallel group study to
 determine the effect of Evolocumab treatment on carotid plaque morphology and composition in
 asymptomatic patients with 50% carotid artery stenosis.

ICD-10 classifications
Occlusion and stenosis of carotid arteryCarotid artery syndrome (hemispheric)Injury of carotid arteryAneurysm and dissection of carotid arteryOcclusion and stenosis of vertebral artery
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03931161
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03931161 through Pure Global AI's free database. This Phase 4 trial is sponsored by Imperial College Healthcare NHS Trust and is currently Recruiting. The study focuses on Carotid Artery Stenosis. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.